[{"id":"0274e43f-cc0c-414e-9481-44dc1368c6ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT05515575","created_at":"2022-09-08T14:56:05.365Z","updated_at":"2025-02-25T13:13:08.083Z","phase":"Phase 2","brief_title":"A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA","source_id_and_acronym":"NCT05515575","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRCA1 • BRCA2 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • CHEK1 • BARD1 • NBN • FANCF • FANCL • XRCC2 • ERCC4 • FANCI • FANCM • RAD52 • FANCD2 • FANCE • FANCG • RAD23B • RECQL4 • RPA1 • ABRAXAS1 • FANCC • RAD54B • SLX4","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • CHEK1 • BARD1 • NBN • FANCF • FANCL • XRCC2 • ERCC4 • FANCI • FANCM • RAD52 • FANCD2 • FANCE • FANCG • RAD23B • RECQL4 • RPA1 • ABRAXAS1 • FANCC • RAD54B • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 08/23/2022","start_date":" 08/23/2022","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-11-05"},{"id":"0908ebfc-d15b-456b-ac37-d0125231481b","acronym":"SUKSES-B2","url":"https://clinicaltrials.gov/study/NCT04939662","created_at":"2021-06-25T22:54:09.478Z","updated_at":"2025-02-25T14:59:57.998Z","phase":"Phase 2","brief_title":"Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects","source_id_and_acronym":"NCT04939662 - SUKSES-B2","lead_sponsor":"Se-Hoon Lee","biomarkers":" BRCA1 • BRCA2 • SLFN11 • BRCA • RAD51 • RAD51B • RAD51C • RAD50 • NBN • RAD54L • WRN • POU2F3 • RAD52 • RECQL5 • RECQL • RECQL4 • RPA1","pipe":" | ","alterations":" RAD51C mutation • RAD51D mutation • RAD51B mutation • BRCA mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • SLFN11 • BRCA • RAD51 • RAD51B • RAD51C • RAD50 • NBN • RAD54L • WRN • POU2F3 • RAD52 • RECQL5 • RECQL • RECQL4 • RPA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAD51C mutation • RAD51D mutation • RAD51B mutation • BRCA mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 06/11/2021","start_date":" 06/11/2021","primary_txt":" Primary completion: 10/27/2023","primary_completion_date":" 10/27/2023","study_txt":" Completion: 10/27/2023","study_completion_date":" 10/27/2023","last_update_posted":"2024-01-01"},{"id":"40c5a9dd-b0cf-48c4-bf22-51d4452040b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03448718","created_at":"2021-01-18T17:00:17.468Z","updated_at":"2025-02-25T14:58:45.009Z","phase":"Phase 2","brief_title":"Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations","source_id_and_acronym":"NCT03448718","lead_sponsor":"Matthew Galsky","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/17/2018","start_date":" 04/17/2018","primary_txt":" Primary completion: 07/14/2021","primary_completion_date":" 07/14/2021","study_txt":" Completion: 10/15/2021","study_completion_date":" 10/15/2021","last_update_posted":"2023-11-22"},{"id":"81487a0e-81e3-441c-b593-12da8e76c7d4","acronym":"SUKSES-B","url":"https://clinicaltrials.gov/study/NCT03009682","created_at":"2021-01-18T06:59:12.038Z","updated_at":"2024-07-02T16:36:34.418Z","phase":"Phase 2","brief_title":"Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations","source_id_and_acronym":"NCT03009682 - SUKSES-B","lead_sponsor":"Samsung Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • RAD51 • RAD51B • RAD51C • RAD50 • NBN • RAD54L • WRN • RAD52 • RECQL5 • RECQL • RECQL4 • RPA1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • BLM mutation • MRE11A mutation • RAD54L mutation • NBN mutation • WRN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation • RPA1 mutation","tags":["BRCA1 • BRCA2 • ATM • RAD51 • RAD51B • RAD51C • RAD50 • NBN • RAD54L • WRN • RAD52 • RECQL5 • RECQL • RECQL4 • RPA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • BLM mutation • MRE11A mutation • RAD54L mutation • NBN mutation • WRN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation • RPA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 01/01/2021","study_completion_date":" 01/01/2021","last_update_posted":"2021-02-18"}]